 "Jubilant Life Sciences hits lifetime high on getting approval for Paroxetine tablets")
Jubilant Life Sciences has moved higher to its lifetime high of Rs 452, up 10% on the BSE, after the company said it has received approval Paroxetine tablets, the generic version of Paxil tablets, which is used as an antidepressant.
“The company has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Paroxetine tablets USP, 10 mg, 20 mg, 30 mg and 40 mg,” Jubilant Life Sciences said in a press release.
This is the generic version of Paxil tablets, 10 mg, 20 mg, 30 mg, and 40 mg® (of Apotex), which is used as an antidepressant, it added.
The company said, as on September 30, 2015, it had a total of 820 filings for formulations of which 391 have been approved in various regions globally. This includes 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe.
At 12:16 PM, the stock was up 8% at Rs 445 on the BSE. The trading volumes on the counter more than doubled with a combined 2.14 million shares changed hands on the BSE and NSE so far.
“The company has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Paroxetine tablets USP, 10 mg, 20 mg, 30 mg and 40 mg,” Jubilant Life Sciences said in a press release.
This is the generic version of Paxil tablets, 10 mg, 20 mg, 30 mg, and 40 mg® (of Apotex), which is used as an antidepressant, it added.
The company said, as on September 30, 2015, it had a total of 820 filings for formulations of which 391 have been approved in various regions globally. This includes 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe.
At 12:16 PM, the stock was up 8% at Rs 445 on the BSE. The trading volumes on the counter more than doubled with a combined 2.14 million shares changed hands on the BSE and NSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%